Sleep Cycle’s Q1 2026 results confirms the transition toward a multi-product platform. While reported figures reflect planned margin compression as the company expands into higher-value markets, the underlying strategic shift is becoming increasingly visible. The market's c14% share price decline following the report appears unjustified, as the results were broadly in line with our estimates and management had already communicated the 5% EBIT margin guidance for 2026, which it has designated as an investment year. For investors with a long-term horizon, the current valuation—at approximately 4x EV/EBIT 2027e—offers a potential entry point to capture the re-acceleration of growth and margin expansion expected from 2027 onwards.
LÄS MER
